Recombinant Poxvirus Vector Expressing CDV Hemagglutinin and GM-CSF

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current canine distemper virus (CDV) vaccines lack optimal efficacy and safety, particularly in field conditions, and do not adequately stimulate hematopoietic cell activity or immune response.

Innovation Solution

Development of recombinant vectors that express CDV hemagglutinin (HA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) proteins to induce an immunological response, using poxvirus-based vectors to enhance vaccine efficacy and safety.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional CDV vaccines are used, then basic vaccination coverage is achieved, but vaccine efficacy and safety are not optimal particularly in field conditions

Engineering Contradiction:

Improvevaccine efficacyVSAvoidperformance in field conditions

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent combines CDV hemagglutinin antigen with GM-CSF adjuvant in a single recombinant poxvirus vector (vCP2392), merging vaccination and immune stimulation functions into one formulation. This integration improves vaccine efficacy by simultaneously delivering the antigen and enhancing immune response, while the single-shot approach improves adaptability for field conditions.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The vaccine uses a composite structure combining poxvirus vector, CDV HA antigen, and GM-CSF adjuvant. This composite approach creates a synergistic effect where the poxvirus delivers the antigen while GM-CSF enhances immune cell activity, resulting in superior efficacy and safety profile compared to conventional vaccines.

Inventive Principle:

Principle #40Composite materials

2Reliability

If heterologous GM-CSF is administered, then some immune stimulation is achieved, but optimum adjuvant effect is not obtained

Engineering Contradiction:

Improveimmune responseVSAvoidadjuvant effectiveness

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the species origin parameter of GM-CSF from heterologous to endogenous (canine), which fundamentally alters its effectiveness. Canine GM-CSF produced by the recombinant poxvirus matches the host species, enabling optimal interaction with canine hematopoietic cells and achieving the desired adjuvant effect that heterologous GM-CSF cannot provide.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If current vaccines are used, then vaccination is administered, but hematopoietic cell activity and immune response are not adequately stimulated

Engineering Contradiction:

Improveimmune response strengthVSAvoidhematopoietic cell stimulation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent introduces GM-CSF as an intermediary substance that mediates between the vaccine antigen and the immune system. GM-CSF acts as a bridge that specifically stimulates hematopoietic cell activity and enhances immune cell recruitment to the vaccination site, thereby amplifying the overall immune response in a controlled and reliable manner.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS10076566B2Recombinant CDV compositions and uses thereof

Publication Date: 2018.09.18 MERIAL LTD

AI summary

The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.